Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05908773 | A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors | EARLY_PHASE1 | COMPLETED | 1 | — | — | Apr 4, 2023 | Sep 18, 2023 | Jan 28, 2025 | 1 | United States |
Measure the percent injected dose per cubic centimeter (%ID/cc) tissue of TTX-MC138-NODAGA-Cu64 in radiographically confirmed metastatic lesions in subjects with advanced solid tumors using PET-MRI.
| Name | Type | Description |
|---|---|---|
| TTX-MC138-NODAGA-Cu64 | DRUG | TTX-MC138-NODAGA-Cu64 solution was developed as a PET radiopharmaceutical to permit assessment of delivery of TMX-MC138 to metastatic lesions in subjects with solid tumors. Subjects will be administered a microdose of TTX-MC138-NODAGA-Cu64 injection administered intravenously followed by whole body PET imaging. |
Inclusion Criteria: 1. Willing and able to provide written informed consent form for the study prior to the performance of any study-specific procedures. 2. Greater than or equal to 18 years of age at the time of screening. 3. Histologically or cytologically confirmed diagnosis of metastatic solid ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |